Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 16/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.45 |
| ▸ | NOS3 | P29474 | 8/20 | 0.45 |
| ▸ | NOS1 | P29475 | 8/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23201070 | 0.91 | NOS2 (0.50) | ADRA1DF2NOS2NOS3NOS1 | |
| Trifluoroacetic Acid SCHEMBL28915050 | 0.90 | ADRA1D (0.44) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| SCHEMBL30711675 | 0.81 | ADRA1D (0.47) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| SCHEMBL27033537 | 0.81 | ADRA1D (0.47) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| SCHEMBL27033816 | 0.80 | ADRA1D (0.52) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| SCHEMBL30711627 | 0.80 | ADRA1D (0.52) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| Lithium Ion SCHEMBL30711636 | 0.79 | ADRA1D (0.45) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| Lithium Ion SCHEMBL29174263 | 0.79 | ADRA1D (0.45) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| SCHEMBL28571348 | 0.78 | ADRA1D (0.50) | ADRA1DF2NOS2CYP2D6SLC6A2 | |
| SCHEMBL23201171 | 0.78 | F2 (0.46) | ADRA1DF2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ADRA1D 4576/4885F2 4188/4885NOS2 2617/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ADRA1D 4576/4885F2 4188/4885NOS2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.